What is the price target for MRTX stock?
22 analysts have analysed MRTX and the average price target is 62.42 USD. This implies a price increase of 6.34% is expected in the next year compared to the current price of 58.7.
MIRATI THERAPEUTICS INC (MRTX) Forecast, Price Target & Analyst Ratings
NASDAQ:MRTX • US60468T1051
Current stock price
58.7 USD
-0.1 (-0.17%)
At close:
58.99 USD
+0.29 (+0.49%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MIRATI THERAPEUTICS INC (MRTX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Feb 26, 2024
- Period
- Q4 / 2023
- EPS Estimate
- -$2.67
- Revenue Estimate
- 25.741M
Price Target Details & History
Consensus Price Target and Range
Mean target
$62.42
Upside
+ 6.34%
From current price of $58.70 to mean target of $62.42, Based on 22 analyst forecasts
Low
$45.45
Median
$60.18
High
$86.10
Price Target Revisions
1 Month
0.84%
3 Months
12.84%
Price Target Summary
22 Wall Street analysts provided a forecast for the next 12 months for MRTX. The average price target is 62.42 USD. This implies a price increase of 6.34% is expected in the next year compared to the current price of 58.7.
The average price target has been revised upward by 12.84% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
69.09%
MRTX was analyzed by 22 analysts. The buy percentage consensus is at 69. So analysts seem to be have mildly positive about MRTX.
In the previous month the buy percentage consensus was at a similar level.
MRTX was analyzed by 22 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-12-20 | Citigroup | Downgrade | Buy -> Neutral |
| 2023-11-07 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2023-11-07 | Stifel | Downgrade | Buy -> Hold |
| 2023-10-10 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2023-10-09 | ScotiaBank | Upgrade | Sector Underperform -> Sector Perform |
| 2023-10-09 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2023-10-09 | B. Riley Securities | Downgrade | Buy -> Neutral |
| 2023-10-09 | Jefferies | Downgrade | Buy -> Hold |
| 2023-10-06 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2023-10-06 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2023-10-06 | Stifel | Reiterate | Buy -> Buy |
| 2023-09-28 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-08-10 | Citigroup | Upgrade | Neutral -> Buy |
| 2023-08-09 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2023-08-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-08-09 | B. Riley Securities | Upgrade | Neutral -> Buy |
| 2023-08-09 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2023-07-27 | ScotiaBank | Initiate | Sector Underperform |
| 2023-07-24 | Guggenheim | Maintains | Buy -> Buy |
| 2023-07-24 | B. Riley Securities | Maintains | Neutral -> Neutral |
| 2023-07-24 | Barclays | Maintains | Overweight -> Overweight |
| 2023-07-14 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2023-06-16 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-05-25 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2023-05-25 | Barclays | Maintains | Overweight -> Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Feb 26, 2024
- Period
- Q4 / 2023
- EPS Estimate
- -$2.67
- Revenue Estimate
- 25.741M
- Revenue Q2Q
- 2,667.85%
- EPS Q2Q
- 23.91%
- Number of Analysts
- 19
Next Earnings Revisions
Revenue (1 Month)
-0.70%
Revenue (3 Months)
2.49%
EPS (1 Month)
-0.83%
EPS (3 Months)
2.99%
Next Earnings Summary
MRTX is expected to report earnings on 2/26/2024. The consensus EPS estimate for the next earnings is -2.67 USD and the consensus revenue estimate is 25.74M USD.
The next earnings revenue estimate has been revised upward by 2.49% in the past 3 months.
Full Analyst Estimates 2023 - 2030
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 13.4M 301.20% | 72.09M 437.99% | 12.44M -82.74% | 62.951M 406.04% | 182.56M 190.00% | 329.19M 80.32% | 505.03M 53.42% | 736.43M 45.82% | 1.026B 39.32% | 1.435B 39.86% | 1.641B 14.36% | |
| EBITDA YoY % growth | -368.72M -66.20% | -571.4M -54.97% | -756.66M -32.42% | -714.041M 5.63% | -645.051M 9.66% | -517.274M 19.81% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -369.36M -66.30% | -573.18M -55.18% | -759.59M -32.52% | -536.499M 29.37% | -550.043M -2.52% | -729.495M -32.63% | -420.601M 42.34% | -194.204M 53.83% | 87.824M 145.22% | 387.13M 340.80% | 571.17M 47.54% | |
| Operating Margin | -2,756.42% | -795.09% | -6,106.03% | -852.25% | -301.29% | -221.60% | -83.28% | -26.37% | 8.56% | 26.98% | 34.81% | |
| EPS YoY % growth | -7.95 -40.96% | -11.17 -40.50% | -13.18 -17.99% | -11.33 14.07% | -9.31 17.83% | -7.77 16.54% | -5.90 24.06% | -2.09 64.52% | 2.01 195.90% | 5.91 194.28% | 6.89 16.64% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -2.67 23.91% | -2.59 18.61% | -2.45 19.31% | -2.31 7.11% | -2.05 23.11% |
| Revenue Q2Q % growth | 25.741M 2,667.85% | 23.208M 223.68% | 33.34M 143.54% | 42.996M 162.17% | 61.149M 137.55% |
| EBITDA Q2Q % growth | -183.6M 12.06% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -157.111M 25.79% | -159.414M 17.75% | -157.684M 15.80% | -145.275M 15.56% | -165.701M -5.47% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
12.15%
EPS Next 5 Year
12.99%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
198.00%
Revenue Next 5 Year
126.18%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-11.53%
EBIT Next 5 Year
N/A
MIRATI THERAPEUTICS INC / MRTX Forecast FAQ
What is the next earnings date for MRTX stock?
MIRATI THERAPEUTICS INC (MRTX) will report earnings on 2024-02-26, after the market close.
Can you provide the consensus estimates for MIRATI THERAPEUTICS INC next earnings?
The consensus EPS estimate for the next earnings of MIRATI THERAPEUTICS INC (MRTX) is -2.67 USD and the consensus revenue estimate is 25.74M USD.
What is the consensus rating for MIRATI THERAPEUTICS INC (MRTX) stock?
The consensus rating for MIRATI THERAPEUTICS INC (MRTX) is 69.0909 / 100 . This indicates that analysts generally have a neutral outlook on the stock.